Tricellular tight junction protein LSR/angulin-1 contributes to the epithelial barrier and malignancy in human pancreatic cancer cell line.
AREG
Growth factors
LSR
Pancreatic cancer
Tricellulin
Journal
Histochemistry and cell biology
ISSN: 1432-119X
Titre abrégé: Histochem Cell Biol
Pays: Germany
ID NLM: 9506663
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
accepted:
23
09
2019
pubmed:
28
10
2019
medline:
15
2
2020
entrez:
26
10
2019
Statut:
ppublish
Résumé
Lipolysis-stimulated lipoprotein receptor (LSR)/angulin-1 is a crucial molecule of tricellular contacts in the epithelial barrier of normal cells and the malignancy of cancer cells. To investigate whether LSR/angulin-1 affects the epithelial barrier and malignancy in human pancreatic cancer, human pancreatic cancer cell line HPAC was used. Treatment with EGF or TGF-β increased the expression of LSR, but not tricellulin (TRIC), and induced the localization of LSR and TRIC to bicellular tight junctions from tricellular tight junctions. TGF-β receptor type-1 inhibitor EW-7197 prevented changes of the distribution and the barrier function of LSR by TGF-β. Knockdown of LSR increased cell migration, invasion, proliferation and EGF ligand amphiregulin expression and decreased the epithelial barrier. Treatment with amphiregulin induced cell migration and invasion and knockdown of amphiregulin prevented the increases of cell migration, invasion and proliferation caused by knockdown of LSR. Treatment with LSR ligand peptide angubindin-1 decreased the epithelial barrier and the expression of LSR, but not TRIC, and increased cell invasion. Knockdown of TRIC decreased cell migration and the epithelial barrier. In immunohistochemical analysis of human pancreatic cancer tissues, LSR and TRIC were found to be localized at the cell membranes of normal pancreatic ducts and well-differentiated pancreatic ductal adenocarcinomas (PDAC), whereas in poorly differentiated PDAC, LSR was weakly detected in the cytoplasm. Amphiregulin was highly expressed in the cytoplasm of well- and poorly differentiated PDAC. In pancreatic cancer, LSR contributes to the epithelial barrier and malignancy via growth factors and may be a potential targeting molecule in the therapy.
Identifiants
pubmed: 31650247
doi: 10.1007/s00418-019-01821-4
pii: 10.1007/s00418-019-01821-4
doi:
Substances chimiques
LSR protein, human
0
Receptors, Lipoprotein
0
Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5-16Références
Gastroenterology. 2001 Sep;121(3):678-84
pubmed: 11522752
Sci Rep. 2016 Sep 19;6:33582
pubmed: 27641742
Tissue Barriers. 2014 May 01;2:e28960
pubmed: 25097825
Int J Mol Sci. 2019 Aug 17;20(16):null
pubmed: 31426497
Semin Cell Dev Biol. 2014 Apr;28:31-41
pubmed: 24463227
J Cell Sci. 2013 Feb 15;126(Pt 4):966-77
pubmed: 23239027
Oncotarget. 2017 Jun 6;8(23):37009-37022
pubmed: 27391068
J Cell Sci. 2011 Feb 15;124(Pt 4):548-55
pubmed: 21245199
Oncogene. 2008 Nov 24;27(55):6930-8
pubmed: 19029935
Am J Physiol Renal Physiol. 2008 Oct;295(4):F867-76
pubmed: 18480174
Anticancer Res. 2016 Nov;36(11):5895-5904
pubmed: 27793914
J Control Release. 2018 Aug 10;283:126-134
pubmed: 29753959
Biochim Biophys Acta. 2009 Apr;1788(4):872-91
pubmed: 19059202
Infect Immun. 2011 Nov;79(11):4353-60
pubmed: 21911469
Oncotarget. 2016 May 10;7(19):27735-52
pubmed: 27036040
Cancer Sci. 2010 Nov;101(11):2351-60
pubmed: 20726858
Biochim Biophys Acta. 2011 Dec;1816(2):119-31
pubmed: 21658434
Sci Rep. 2017 Jan 10;7:37049
pubmed: 28071680
Cancer Res. 1994 Aug 1;54(15):3959-62
pubmed: 8033121
Oncol Lett. 2017 Dec;14(6):6776-6782
pubmed: 29151917
Anticancer Res. 2016 Mar;36(3):1287-93
pubmed: 26977027
J Control Release. 2017 Aug 28;260:1-11
pubmed: 28528740
Semin Cell Dev Biol. 2014 Dec;36:224-31
pubmed: 25239399
Trends Cell Biol. 2006 Apr;16(4):181-8
pubmed: 16537104
J Cell Biol. 2005 Dec 19;171(6):939-45
pubmed: 16365161
Histopathology. 2012 May;60(6B):E76-86
pubmed: 22394074
Signal Transduct Target Ther. 2018 Apr 20;3:11
pubmed: 29682330